NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
28
KPTI Quote, Financials, Valuation and Earnings
Last price:
$0.64
Seasonality move
:
14.23%
Day range:
$0.63 - $0.66
52-week range:
$0.63 - $1.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.55x
P/B ratio:
--
Volume:
1.3M
Avg. volume:
872.5K
1-year change:
-14.97%
Market cap:
$80.8M
Revenue:
$146M
EPS (TTM):
-$1.14
Analysts' Opinion
-
Consensus RatingKaryopharm Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Karyopharm Therapeutics has an estimated upside of 598% from its current price of $0.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.64.
Fair Value
-
According to the consensus of 0 analysts, Karyopharm Therapeutics has 598% upside to fair value with a price target of -- per share.
KPTI vs. S&P 500
-
Over the past 5 trading days, Karyopharm Therapeutics has underperformed the S&P 500 by -6.03% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Karyopharm Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Karyopharm Therapeutics has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Karyopharm Therapeutics reported revenues of $38.8M.
Earnings Growth
-
Karyopharm Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Karyopharm Therapeutics reported earnings per share of -$0.26.
Enterprise value:
137.9M
EV / Invested capital:
4.45x
Price / LTM sales:
0.55x
EV / EBIT:
--
EV / Revenue:
0.93x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$142.3M
Return On Assets:
-39.11%
Net Income Margin (TTM):
-58.93%
Return On Equity:
--
Return On Invested Capital:
-221.89%
Operating Margin:
-67.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $249.8M | $145.9M | $148.4M | $36M | $38.8M | |
| Gross Profit | $245.7M | $140.5M | $142.3M | $35.1M | $37.5M | |
| Operating Income | -$61.4M | -$125.6M | -$126M | -$31.3M | -$26.3M | |
| EBITDA | -$60.2M | -$115.4M | -$54.4M | -$28.3M | -$20.6M | |
| Diluted EPS | -$1.14 | -$1.32 | -$1.14 | -$0.30 | -$0.26 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $285.4M | $241.6M | $222.7M | $263.2M | $184.8M | |
| Total Assets | $337.6M | $254.1M | $231.2M | $270M | $189.5M | |
| Current Liabilities | $52.6M | $68.9M | $61.8M | $62.1M | $61.5M | |
| Total Liabilities | $253.8M | $380.1M | $371.5M | $370.4M | $349.1M | |
| Total Equity | $83.8M | -$126M | -$140.3M | -$100.4M | -$159.6M | |
| Total Debt | $115.8M | $169.1M | $169.9M | $170.7M | $190.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$97.2M | -$101M | -$120.3M | -$29.5M | -$19.5M | |
| Cash From Investing | -$8.2M | -$84.2M | $107.5M | -$7.7M | $7.5M | |
| Cash From Financing | $38.8M | -- | -- | -- | -- | |
| Free Cash Flow | -$97.1M | -$101M | -$120.5M | -$29.5M | -$19.5M | |
KPTI
Sector
Market Cap
$80.8M
$43.9M
Price % of 52-Week High
33.06%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-14.97%
-29.11%
Beta (5-Year)
0.048
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.68
200-day SMA
Sell
Level
$0.96
Bollinger Bands (100)
Sell
Level
0.74 - 0.88
Chaikin Money Flow
Sell
Level
-164.1M
20-day SMA
Sell
Level
$0.76
Relative Strength Index (RSI14)
Sell
Level
26.25
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-91.656
50-day SMA
Sell
Level
$0.82
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Sell
Level
-4.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.7048)
Sell
CA Score
(Annual)
Level (-5.5336)
Buy
Beneish M-Score
(Annual)
Level (-2.9144)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (8.6336)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Stock Forecast FAQ
In the current month, KPTI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KPTI average analyst price target in the past 3 months is --.
-
Where Will Karyopharm Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Karyopharm Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Karyopharm Therapeutics?
Analysts are divided on their view about Karyopharm Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Karyopharm Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Karyopharm Therapeutics's Price Target?
The price target for Karyopharm Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KPTI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Karyopharm Therapeutics is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KPTI?
You can purchase shares of Karyopharm Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Karyopharm Therapeutics shares.
-
What Is The Karyopharm Therapeutics Share Price Today?
Karyopharm Therapeutics was last trading at $0.64 per share. This represents the most recent stock quote for Karyopharm Therapeutics. Yesterday, Karyopharm Therapeutics closed at $0.64 per share.
-
How To Buy Karyopharm Therapeutics Stock Online?
In order to purchase Karyopharm Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 2.5% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 3.2% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 6.14% over the past day.
